These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 36591729)
1. Cost-effectiveness analysis of pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer. Liu T; Liu S; Guan S; Tai Y; Jin Y; Dong M J Chemother; 2023 Dec; 35(8):745-752. PubMed ID: 36591729 [TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment for mismatch-repair-deficient (dMMR) or microsatellite-instability-high (MSI-H) advanced or metastatic colorectal cancer from the perspective of the Chinese health-care system. Zhu C; Han G; Wu B BMC Health Serv Res; 2023 Oct; 23(1):1083. PubMed ID: 37821934 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States. Aguiar-Ibáñez R; Hardern C; van Hees F; Lee D; Patel A; Chhabra N; Baluni G; Amonkar M; Lai Y; Xu R; Massaad R; Fogelman D J Med Econ; 2022; 25(1):469-480. PubMed ID: 35184650 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of pembrolizumab compared with chemotherapy in the US for women with previously treated deficient mismatch repair or high microsatellite instability unresectable or metastatic endometrial cancer. Thurgar E; Gouldson M; Matthijsse S; Amonkar M; Marinello P; Upadhyay N; Nwankwo C; Aguiar-Ibáñez R J Med Econ; 2021; 24(1):675-688. PubMed ID: 33866938 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France. Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550 [TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. Chu JN; Choi J; Ostvar S; Torchia JA; Reynolds KL; Tramontano A; Gainor JF; Chung DC; Clark JW; Hur C Cancer; 2019 Jan; 125(2):278-289. PubMed ID: 30343509 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores. Zhou K; Jiang C; Li Q Lung Cancer; 2019 Oct; 136():98-101. PubMed ID: 31476529 [TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC. Chen P; Wang X; Zhu S; Li H; Rui M; Wang Y; Sun H; Ma A Front Public Health; 2022; 10():956792. PubMed ID: 36016894 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US. Insinga RP; Vanness DJ; Feliciano JL; Vandormael K; Traore S; Burke T J Med Econ; 2018 Dec; 21(12):1191-1205. PubMed ID: 30188231 [TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancer. Yoshino T; Andre T; Kim TW; Yong WP; Shiu KK; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Alcaide-Garcia J; Gibbs P; de la Fouchardiere C; Rivera F; Elez E; Le DT; Adachi N; Fogelman D; Marinello P; Diaz LA Cancer Sci; 2023 Mar; 114(3):1026-1036. PubMed ID: 36369901 [TBL] [Abstract][Full Text] [Related]
11. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial. Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer. Aziz MIA; Tan LE; Tan WHG; Toh CK; Loke LPY; Pearce F; Ng K J Med Econ; 2020 Sep; 23(9):952-960. PubMed ID: 32462958 [No Abstract] [Full Text] [Related]
13. Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA. Zeng X; Wan X; Peng L; Peng Y; Ma F; Liu Q; Tan C BMJ Open; 2019 Dec; 9(12):e031019. PubMed ID: 31831534 [TBL] [Abstract][Full Text] [Related]
14. Cost-Utility Analysis of Pembrolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer With Different PD-L1 Expression Levels. Weng X; Luo S; Lin S; Zhong L; Li M; Xin R; Huang P; Xu X Oncol Res; 2020 Mar; 28(2):117-125. PubMed ID: 31610828 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of pembrolizumab in patients with treatment-refractory metastatic colorectal cancer in Japan. Sugiura K; Hiratsuka H; Oshima G; Aiko S Jpn J Clin Oncol; 2023 Jul; 53(8):691-697. PubMed ID: 37259600 [TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness Analysis of Pembrolizumab in Patients With Advanced Esophageal Cancer Based on the KEYNOTE-181 Study. Zhan M; Xu T; Zheng H; He Z Front Public Health; 2022; 10():790225. PubMed ID: 35309225 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater. She L; Hu H; Liao M; Xia X; Shi Y; Yao L; Ding D; Zhu Y; Zeng S; Shen L; Huang J; Carbone DP Lung Cancer; 2019 Dec; 138():88-94. PubMed ID: 31655368 [TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China. Liao W; Huang J; Hutton D; Li Q J Med Econ; 2019 Apr; 22(4):344-349. PubMed ID: 30646794 [TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness of First-Line Versus Second-Line Pembrolizumab or Chemotherapy in Patients With Microsatellite-Instability-High/Mismatch Repair-Deficient Advanced Colorectal Cancer. Chongqing T; Sini L; Xiaohui Z; Liubao P; Ye P; Shuxia Q; Liting W; Meiyu W; Xiaomin W Front Pharmacol; 2021; 12():802942. PubMed ID: 34970153 [No Abstract] [Full Text] [Related]
20. Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland. Bhadhuri A; Insinga R; Guggisberg P; Panje C; Schwenkglenks M Swiss Med Wkly; 2019 Dec; 149():w20170. PubMed ID: 31880807 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]